Targeting Liver Sinusoidal Endothelial Cells: An Attractive Therapeutic Strategy to Control Inflammation in Nonalcoholic Fatty Liver Disease
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD), especially its advanced stage nonalcoholic steatohepatitis (NASH), has become a threatened public health problem worldwide. However, no specific drug has been approved for clinical use to treat patients with NASH, though there are many promising candidates against NAFLD in the drug development pipeline. Recently, accumulated evidence showed that liver sinusoidal endothelial cells (LSECs) play an essential role in the occurrence and development of liver inflammation in patients with NAFLD. LSECs, as highly specialized endothelial cells with unique structure and anatomical location, contribute to the maintenance of liver homeostasis and could be a promising therapeutic target to control liver inflammation of NAFLD. In this review, we outline the pathophysiological roles of LSECs related to inflammation of NAFLD, highlight the pro-inflammatory and anti-inflammatory effects of LSECs, and discuss the potential drug development strategies against NAFLD based on targeting to LSECs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286
Autophagy in Human Health and Disease
Choi, A. M. K., Ryter, S. W., & Levine, B. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1205406 · Cited by 2,583
Chiu, J.-J., & Chien, S. (2011) · Physiological Reviews · doi:10.1152/physrev.00047.2009 · Cited by 2,280
Non-alcoholic fatty liver disease - a global public health perspective
Younossi, Z. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.033 · Cited by 2,149
Liver inflammation and fibrosis
Koyama, Y., & Brenner, D. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88881 · Cited by 1,295 · cited 9×
“In NAFLD, infiltrated leukocytes are recruited from the circulation, mainly bone marrow-derived macrophages (BMMs) and neutrophils, into liver parenchyma, and this leads to the formation of inflammatory foci, and thus accelerates the disease progression from simple steatosis to steatohepatitis (Rinella, 2015).”
BackgroundInfluentialLiver sinusoidal endothelial cells: Physiology and role in liver diseases
Poisson, J., Lemoinne, S., Boulanger, C., Durand, F., Moreau, R., Valla, D., & Rautou, P.-E. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.009 · Cited by 1,047
Decoding cell death signals in liver inflammation
Brenner, C., Galluzzi, L., Kepp, O., & Kroemer, G. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.03.033 · Cited by 1,022 · cited 1×
“Although a moderate and resolved inflammatory response contributes to homeostasis remodeling and tissue repair and thereby has hepatoprotective effects, inflammation in NASH is persistent, which leads to hepatocyte death and liver parenchymal damage (Brenner et al., 2013).”
BackgroundTriggering and resolution of inflammation in NASH
Schuster, S., Cabrera, D., Arrese, M., & Feldstein, A. E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0009-6 · Cited by 943
Kubes, P., & Jenne, C. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052415 · Cited by 923
Scavenger receptors in homeostasis and immunity
Canton, J., Neculai, D., & Grinstein, S. (2013) · Nature Reviews Immunology · doi:10.1038/nri3515 · Cited by 838
Limmer, A., Ohl, J., Kurts, C., Ljunggren, H.-G., Reiss, Y., Groettrup, M., Momburg, F., Arnold, B., & Knolle, P. A. (2000) · Nature Medicine · doi:10.1038/82161 · Cited by 758
Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis
Schwabe, R. F., Tabas, I., & Pajvani, U. B. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.311 · Cited by 671
Hernández–Gea, V., Ghiassi–Nejad, Z., Rozenfeld, R., Gordon, R., Fiel, M. I., Yue, Z., Czaja, M. J., & Friedman, S. L. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.044 · Cited by 654
Capillarization of hepatic sinusoids in man
Schaffner, F., & Popper, H. (1963) · Gastroenterology · doi:10.1016/s0016-5085(63)80130-4 · Cited by 610
Selectins: initiators of leucocyte adhesion and signalling at the vascular wall
McEver, R. P. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv154 · Cited by 575 · cited 1×
“…endogenous glycoproteins and microbial glycans, the recruitment of lysosomal enzymes, and the endocytosis of other tissue turnover waste products including collagen alpha chains, tissue plasminogen activator (Stahl and Ezekowitz, 1998; Lee et al., 2002; McGreal et al., 2004; Sorensen et al., 2012).”
BackgroundLiver sinusoidal endothelial cells — gatekeepers of hepatic immunity
Shetty, S., Lalor, P. F., & Adams, D. H. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0020-y · Cited by 523
Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2
Miura, K., Yang, L., van Rooijen, N., Ohnishi, H., & Seki, E. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00365.2011 · Cited by 503 · cited 3×
“Blocking these molecules or their ligands is efficacious to control inflammation in various NASH models (Edwards et al., 2005; Weston et al., 2015; Miyachi et al., 2017; Hammoutene and Rautou, 2019).”
BackgroundHepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9
Garcia-Martinez, I., Santoro, N., Chen, Y., Hoque, R., Ouyang, X., Caprio, S., Shlomchik, M. J., Coffman, R. L., Candia, A., & Mehal, W. Z. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83885 · Cited by 498 · cited 2×
“In NASH, EVs released by hepatocytes under pressure stimulation contribute to the occurrence of liver inflammation by inducing proinflammatory cytokines expression and activating macrophage chemotaxis and thus promoting macrophages recruitment (Hirsova et al., 2016a; Garcia-Martinez et al., 2016; Ibrahim et al., 2016;…”
BackgroundLiver sinusoidal endothelial cells in hepatic fibrosis
DeLeve, L. D. (2015) · Hepatology · doi:10.1002/hep.27376 · Cited by 482 · cited 1×
“…which the size and number of fenestrae vary in different positions and can be changed dynamically depending on physiological states such as fasting or pathological states (Wisse et al., 1985; O’Reilly et al., 2010; Xie et al., 2010; DeLeve, 2015; Monkemoller et al., 2015; Zapotoczny et al., 2019).”
BackgroundThe portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease
Gadd, V. L., Skoien, R., Powell, E. E., Fagan, K. J., Winterford, C., Horsfall, L., Irvine, K., & Clouston, A. D. (2014) · Hepatology · doi:10.1002/hep.26937 · Cited by 452 · cited 1×
“In NASH patients, an expansion of KCs is an early phenomenon, earlier than the recruitment of other immune cells (Gadd et al., 2014).”
BackgroundDeLeve, L. D., Wang, X., & Guo, Y. (2008) · Hepatology · doi:10.1002/hep.22351 · Cited by 408
Self-citationAutophagy in liver diseases: Time for translation?
Allaire, M., Rautou, P.-E., Codogno, P., & Lotersztajn, S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.01.026 · Cited by 378 · cited 1×
“differential roles in chronic liver diseases (Choi et al., 2013; Allaire et al., 2019).”
Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease
Hammoutene, A., & Rautou, P.-E. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.012 · Cited by 364
Diehl, L., Schurich, A., Grochtmann, R., Hegenbarth, S., Chen, L., & Knolle, P. A. (2008) · Hepatology · doi:10.1002/hep.21965 · Cited by 291 · cited 1×
“…by using SRs and induce tolerant naive CD8+ T cells through enhanced interaction between programmed cell death one ligand one on LSECs and programmed cell death protein one on CD8+ T cells (Limmer et al., 2000; Limmer et al., 2005; Burgdorf et al., 2007; Diehl et al., 2008; Shetty et al., 2018).”
BackgroundAngiogenesis in chronic liver disease and its complications: Angiogenesis in CLD
Coulon, S., Heindryckx, F., Geerts, A., Van Steenkiste, C., Colle, I., & Van Vlierberghe, H. (2011) · Liver International · doi:10.1111/j.1478-3231.2010.02369.x · Cited by 276
Macrophage autophagy protects against liver fibrosis in mice
Lodder, J., Denaës, T., Chobert, M.-N., Wan, J., El-Benna, J., Pawlotsky, J.-M., Lotersztajn, S., & Teixeira-Clerc, F. (2015) · Autophagy · doi:10.1080/15548627.2015.1058473 · Cited by 266
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis
Harrison, S. A., Goodman, Z., Jabbar, A., Vemulapalli, R., Younes, Z. H., Freilich, B., Sheikh, M. Y., Schattenberg, J. M., Kayali, Z., Zivony, A., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.11.024 · Cited by 260 · cited 1×
“Unfortunately, the latest clinic outcomes of selonsertib (an ASK1 inhibitor) and emricasan (a pan-caspase inhibitor) are not satisfied (Loomba et al., 2018; Harrison et al., 2020; Ratziu et al., 2020; Romero et al., 2020).”
BackgroundDoulias, P.-T., Tenopoulou, M., Greene, J. L., Raju, K., & Ischiropoulos, H. (2013) · Science Signaling · doi:10.1126/scisignal.2003252 · Cited by 250
Ibrahim, S. H., Hirsova, P., Tomita, K., Bronk, S. F., Werneburg, N. W., Harrison, S. A., Goodfellow, V. S., Malhi, H., & Gores, G. J. (2016) · Hepatology · doi:10.1002/hep.28252 · Cited by 232
The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis
Cai, J., Zhang, X., & Li, H. (2019) · Hepatology · doi:10.1002/hep.30506 · Cited by 207
Hammoutene, A., Biquard, L., Lasselin, J., Kheloufi, M., Tanguy, M., Vion, A.-C., Mérian, J., Colnot, N., Loyer, X., Tedgui, A., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.028 · Cited by 188 · cited 9×
“AFM, atomic forcemicroscopy; CafD, cafeteria diet; CDAA, choline-deficient l-amino acid-defined; HFD, high fat diet; HFGFD, high fat glucose-fructose diet; MCD,methionine and choline deficient; N/A, not applicable; SEM, scanning electron microscopy Frontiers in Pharmacology | www.frontiersin.org April 2021 | Volume 12…”
BackgroundInfluentialLimmer, A., Ohl, J., Wingender, G., Berg, M., Jüngerkes, F., Schumak, B., Djandji, D., Scholz, K., Klevenz, A., Hegenbarth, S., et al. (2005) · European Journal of Immunology · doi:10.1002/eji.200526034 · Cited by 169
Tateya, S., Rizzo, N. O., Handa, P., Cheng, A. M., Morgan-Stevenson, V., Daum, G., Clowes, A. W., Morton, G. J., Schwartz, M. W., & Kim, F. (2011) · Diabetes · doi:10.2337/db11-0255 · Cited by 138
Autophagy in chronic liver diseases: the two faces of Janus
Gual, P., Gilgenkrantz, H., & Lotersztajn, S. (2017) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00295.2016 · Cited by 91
Kodama, K., Toda, K., Morinaga, S., Yamada, S., & Butte, A. J. (2015) · Diabetes · doi:10.2337/db14-0149 · Cited by 85
McMahan, R. H., Porsche, C. E., Edwards, M. G., & Rosen, H. R. (2016) · PLOS ONE · doi:10.1371/journal.pone.0159217 · Cited by 55 · cited 1×
“…for the survival of LSECs in the case of lipid induction, and it also may be involved with signal transducer and activator of transcription 3 (STAT3) for its expression in LSECs alleviated mice liver inflammation induced by alcohol (Miller et al., 2010; Hang et al., 2012; McMahan et al., 2016).”
BackgroundXing, Y., Zhao, T., Gao, X., & Wu, Y. (2016) · Scientific Reports · doi:10.1038/srep21309 · Cited by 45 · cited 2×
“Although LXR agonists have shown therapeutic potential in anti-inflammatory and antifibrotic aspects, whether these beneficial effects are mainly through alleviating the capillarization of LSECs still needs further exploration (Xing et al., 2016).”
Background
Cited by
Necroptosis contributes to chronic inflammation and fibrosis in aging liver
Mohammed, S., Thadathil, N., Selvarani, R., Nicklas, E. H., Wang, D., Miller, B. F., Richardson, A., & Deepa, S. S. (2021) · Aging Cell · doi:10.1111/acel.13512 · Cited by 192
Guo, W., Li, Z., Anagnostopoulos, G., Kong, W. T., Zhang, S., Chakarov, S., Shin, A., Qian, J., Zhu, Y., Bai, W., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.08.016 · Cited by 109
Biagioli, M., Marchianò, S., di Giorgio, C., Roselli, R., Bordoni, M., Bellini, R., Fiorillo, B., Sepe, V., Catalanotti, B., Cassiano, C., et al. (2023) · Hepatology · doi:10.1002/hep.32787 · Cited by 28
The pivotal role of dysregulated autophagy in the progression of non-alcoholic fatty liver disease
Shen, Q., Yang, M., Wang, S., Chen, X., Chen, S., Zhang, R., Xiong, Z., & Leng, Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1374644 · Cited by 15
“Conversely, the dysfunction of LSECs are an early event in the progression of NAFLD, leading to impaired hepatic lipid uptake and metabolism, in fl ammation, and hepatocyte damage (120 – 122).”
Background
Metadata
- Authors
- Wang, X.-K., & Peng, Z.-G.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2021-04-15
- Volume
- 12
- Pages
- 655557-655557
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W3156375891
- Cited by
- 40
- References
- 37
- FWCI
- 4.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.